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ABSTRACT
Background: Smoking is one of the most serious health care issues worldwide, 
as one third to one half of all people who smoke eventually use tobacco habitually. 
Chronic smoke exposure causes airway and lung parenchymal inflammation and the
destruction of alveolar cell walls. Statins may have anti-inflammatory effects that
would play a role in preventing the cellular damage associated with smoking. 
Objective: The aim of this study was to investigate whether atorvastatin pro-
tects against smoking-induced inflammation in alveolar epithelial type I (ATI) and 
type II (ATII) cells in the lungs of rats.
Methods: Adult male albino Wistar rats (200–250 g) were randomly divided 
into 3 groups and exposed to cigarette smoke 8 hours per day for 15 days. During that 
15-day period, the 2 treatment groups received atorvastatin 0.5 or 1.0 mg/kg/d in 2 mL 
of methyl cellulose solution and the control group received 2 mL of methyl cellulose 
solution alone, all via nasogastric catheter. After the 15 days, the lungs were excised
and the tissues were examined by transmission electron microscopy. 
Results: Thirty rats were divided into 3 groups of 10 rats each. All rats sur-
vived the 15 days. In the atorvastatin 0.5-mg group, no changes were found in the
ATI cells or in the blood–air barrier. In the atorvastatin 1.0-mg group, we observed
hyperplasia in the common basal membranes. Hypertrophy, mitochondrial crystolysis 
(MC), and intracytoplasmic edema (ICE) were detected in the ATI cells in the 1.0-mg
group, while chromatin condensation, atrophic appearance, cell shrinkage, and cyto-
plasmic vacuolization were observed in the ATII cells. The rough endoplasmic reticu-
lum (rER) tubules of the ATII cells appeared spiral-shaped. In the control group,
minimal ICE was detected in the ATI cells. However, microvillus deformation, pseu-
dopod formation, edema, mitochondrial swelling, and MC were observed in the ATII 
cells. We also observed MC, several pinocytic vesicles, and normal rER tubules in the 
endothelial cells of the control group.
Conclusions: The administration of atorvastatin 0.5 mg/kg/d was associated 
with some attenuation of lung injury caused by smoke inhalation in these rat lungs. 
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However, atorvastatin 1.0 mg/kg/d was associated with lung damage. Future studies 
are needed to evaluate the dose–response relationship of atorvastatin to smoking-
induced alveolar damage. (Curr Ther Res Clin Exp. 2009;70:366–376) © 2009 Ex-
cerpta Medica Inc.
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INTRODUCTION
Smoking is one of the most serious health care issues worldwide, as one third to one 
half of all people who smoke eventually use tobacco habitually.1 Tobacco use was
found to be associated with 1 in 10 deaths among adults, amounting to >5 million
deaths annually worldwide.2 Between 2002 and 2030, tobacco-attributable deaths are
projected to decline by 9% in high-income countries and to increase by 50% to 6.8 mil-
lion deaths in low- and middle-income countries.3 Unless urgent action is taken, the
annual death toll from tobacco use may rise to >8 million worldwide by 2030.3,4
Chronic smoke exposure causes airway and lung parenchymal inflammation and de-
struction of alveolar cell walls.5,6 Cigarette smoke is associated with chronic obstructive
pulmonary disease (COPD), cancer, chronic bronchitis, and asthma, as well as sub-
optimal lung growth in preadolescent and adolescent smokers.7 Cigarette smoking is
the most common risk factor for developing COPD, which is a disease associated with 
an abnormal inflammatory response of the lungs to noxious particles or gases.5
There are 2 types of lung tissue alveolar epithelial cells: type I (ATI) and type II
(ATII) (the latter includes alveolar epithelial stem cells). Repair of the damaged alveo-
lar surface depends on the ability of ATII cells to differentiate into pre-ATI cells.8 The
alveoli constitute a major trafficking site of inflammatory cells that can ultimately
migrate through the airways and into parenchymal tissue.9
Statins, or 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, are used
clinically for their cholesterol-lowering properties.10 The roles of statins in coronary 
artery disease are well reported. Some studies have focused on the mechanisms in-
volved in the anti-inflammatory effects of statins.11–15
Lee et al,16 in their controlled study of rats administered oral simvastatin 5 mg/kg
once per day for 16 weeks, found that simvastatin was associated with a dose-related 
decrease in cigarette smoking–induced structural and functional derangement of 
the lungs of rats, possibly by reducing inflammatory infiltration, inhibiting ma-
trix metalloproteinase-9 induction, and preventing pathologic changes in pulmo-
nary vasculature. Simvastatin has been reported to inhibit lung cell destruction
caused by 16 weeks of cigarette smoking.16
We conducted this study to assess whether atorvastatin protects against smoking-
induced inflammation in ATI and ATII cells in the lungs of rats.
MATERIALS AND METHODS
Adult male albino Wistar rats weighing 200 to 250 g were used in this experimental
study. All rats were given standard rat chow and tap water ad libitum. This study was
carried out according to the principles of the Declaration of Helsinki.
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Experimental Conditions 
On the first study day, the rats were randomly divided into 3 groups using the
envelope method: the atorvastatin 0.5- and 1.0-mg groups and the control group.
All the rats were housed in the same room, which was 7 m3 in size, and were kept
at 20°C (±2°C) under a 12-hour light/dark regimen in stainless steel cages.
Atorvastatin Preparation and Administration
All 3 groups were exposed to cigarette smoke 8 hours a day for 15 days (equivalent
to 10 standard cigarettes). During the same 15-day period, the atorvastatin groups
received 0.5 or 1.0 mg/kg/d of atorvastatin dissolved in 2 mL methyl cellulose solution
and the control group received 2 mL of methyl cellulose solution alone, all via a naso-
gastric catheter in the morning.
Procedure
The rats were euthanized using ether anesthesia. The lungs were excised and fixed
in 2.5% phosphate-buffered glutaraldehyde for histopathologic evaluation. Samples of 
semithin cross-sections of the lung tissues were prepared with an ultramicrotome,
stained with toluidine blue, and examined using a photomicroscope. After the selec-
tion of appropriate specimens, the tissues, which were stained with uranyl citrate and 
lead acetate, were screened by transmission electron microscopy (TEM) (JEOL 1010,
JEOL Ltd., Tokyo, Japan). The same tissue samples were examined in 2 different centers
by 2 different independent histologists, both of whom were blinded to the treatment 
the rats received. The findings of the 2 histologists were consistent with each other. 
RESULTS
Thirty adult male albino Wistar rats were divided into 3 groups of 10 rats each. All 
rats survived the 15-day study period.
Atorvastatin 0.5-mg Group
No changes were detected in the ATI cells, the blood–air barrier, or the cellular
organelles of the rats in the atorvastatin 0.5-mg group. The common basal membranes 
of the ATI and capillary endothelial cells were normal (Figure 1A). Minimal increases
in collagen fibril structure were observed in the interstitial areas (Figure 1B). Only
minimal changes in the mitochondria and microvilli in the ATII cells were noted on 
examination of the ATI and ATII cells located beneath the collagen matrix. The lyso-
somes were normally shaped, and minimal intracellular edema was detected in the
ATI cells (Figure 1C).
Atorvastatin 1.0-mg Group
Hyperplasia in the common basal membranes of the ATI and capillary endothelial
cells was observed in the lung tissue of the atorvastatin 1.0-mg group. Hypertrophy, 
mitochondrial crystolysis (MC), and intracytoplasmic edema (ICE) were detected in 
the ATI cells (Figure 2A). A widespread increase of collagen fibrils was seen in the
interalveolar septa (Figure 2B). Chromatin condensation, atrophy, cell shrinkage, and 
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Figure 1B. Low magnification of interstitium of lung tissue of rats in the atorvastatin 
0.5-mg group showing minimal increases in the interstitial collagen fibrils (Co) 
and vacuoles (Va) (uranyl acetate-lead citrate; magnification x4400).
Co
Va
Co
Figure 1A. High magnification of lung tissue of rats in the atorvastatin 0.5-mg group 
showing alveolar epithelial type I (T1) cells with normal common basal mem-
brane (BM), intracytoplasmic edema (*), mitochondrial crystolysis (+) and 
endothelial cells (En) (uranyl acetate-lead citrate; magnification x12,000).
T1
BM
En
+
*
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cytoplasmic vacuolization were seen in the ATII cells (Figure 2C). The rough endo-
plasmic reticulum (rER) tubules in the ATII cells were spiral-shaped, closely resem-
bling cells undergoing apoptosis (Figure 2D).
Control Group
Minimal ICE and partial separation were observed in the ATI nuclear membranes
of rats in the control group. MC and several pinocytic vesicles were seen in the capil-
lary endothelial cells. Furthermore, the rER tubules of the capillary endothelial cells
were of normal shape and size (Figure 3A). Microvillus deformation, pseudopod
formation, edema, mitochondrial swelling, and MC were detected in the ATII cells; 
all intracellular lipid droplets were clear, mature lamellar bodies were absent, and the 
rER tubules were inactive (Figure 3B).
DISCUSSION
In the present study, administration of atorvastatin 0.5 mg/kg/d was associated with
decreased ATI and ATII cellular inflammation. Therefore, atorvastatin may protect
against smoking-induced alveolar inflammation at this dosage. However, the ad-
ministration of atorvastatin 1.0 mg/kg/d was associated with ATI and ATII cellular
degeneration and apoptotic processes. We observed ultrastructural changes and an
inflammatory response in the ATI and ATII cells in the control group. These findings 
suggest that atorvastatin 1.0 mg/kg/d may bypass an inflammatory response, leading
Figure 1C. High magnification of lung tissue of rats in the atorvastatin 0.5-mg group 
showing alveolar epithelial type II (T2) cells with minimal changes in mito-
chondria (M) such as mitochondrial crystolysis (+), microvilli (Mv), and alveolar
epithelial type I (T1) cells showing minimal intracytoplasmic edema (*); lipid
droplets (L), and vacuoles (Va) (uranyl acetate-lead citrate; magnification
x12,000).
T1
BM
Mv
M
M
L
L
T2Va
*
+
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Figure 2B. Low magnification of lung tissue of rats in the atorvastatin 1.0-mg group 
showing interalveolar septa with an increase in collagen fibrils (Co) (uranyl
acetate-lead citrate; magnification x4400).
Co
Co
Figure 2A. Low magnification of lung tissue of rats in the atorvastatin 1.0-mg group show-
ing alveolar epithelial type I (T1) cells with hyperplasia of the endothelial cells
(En) and common basal membrane (BM), mitochondrial crystolysis (+), and in-
tracytoplasmic edema (*) (uranyl acetate-lead citrate; magnification x4400).
En
+
+
T1
BM
*
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Figure 2C. High magnification of lung tissue of rats in the atorvastatin 1.0-mg group 
showing alveolar epithelial type II (T2) cells with chromatin condensation
(CC), atrophy, cell shrinkage (CS), vacuoles (Va), pseudopods (Ps), mito-
chondrial crystolysis (+), and collagen fibrils (Co) (uranyl acetate-lead
citrate; magnification x7000).
+
+
CC
Va CS
T2
Ps
Figure 2D. Low magnification of lung tissue of rats in the atorvastatin 1.0-mg group show-
ing alveolar epithelial type II (T2) cells with spiral-shaped rough endoplasmic 
reticulum (rER), nucleus (N), and mitochondrial crystolysis (+) (uranyl acetate-
lead citrate; magnification x4400).
+
N
rER
N
Co
T2
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Figure 3B. High magnification of lung tissue of rats in the control group showing alveolar
epithelial type II (T2) cells with deformed microvilli (MV), pseudopods (Ps), 
edema, mitochondrial swelling (Ms), mitochondrial crystolysis (+), and clear
intracellular lipid droplets (uranyl acetate-lead citrate; magnification
x12,000).
MV
+
Ms
Ps
+
Figure 3A. High magnification of lung tissue of rats in the control group showing alveolar
epithelial type I (T1) cells with minimal intracytoplasmic edema (*), mito-
chondrial crystolysis (+), and normal rough endoplasmic reticulum (rER) (ura-
nyl acetate-lead citrate; magnification x12,000).
rER *
T1
+
T2
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to the development of irreversible changes in the structure of the ATI and ATII cells. Our
findings regarding the protective anti-inflammatory effects of atorvastatin 0.5 mg/kg/d 
are similar to those of previous studies.17–19 However, our observations of the 1.0-mg/kg/d
dosage of atorvastatin on alveolar inflammation contradict those of previous reports.17–19
To our knowledge, this was the first study to find that atorvastatin 1.0 mg/kg/d has 
apoptotic effects on pulmonary cells directly exposed to cigarette smoke. 
In this study, we observed MC, several pinocytic vesicles, and normal capillary 
endothelial cell rER tubules in the lungs of rats in the control group. We detected 
no changes in the capillary endothelial cell organelles of the rats administered
atorvastatin 0.5 mg/kg/d. In addition, the common basal membrane appeared to 
be almost normal. These findings suggest that atorvastatin 0.5 mg/kg/d may pro-
vide protection against smoking-induced inflammation in pulmonary capillary
endothelial cells. However, in the rats administered atorvastatin 1.0 mg/kg/d,
we observed hyperplasia in the common basal membrane, hypertrophy in the en-
dothelial cells, and MC. Our findings, that this atorvastatin dosage may be associ-
ated with hazardous effects on endothelial cells, need to be confirmed. The find-
ings in the 1.0-mg atorvastatin group were not similar to those in the control
group.
We detected chromatin condensation, atrophy, cell shrinkage, and cytoplasmic 
vacuolization in the nuclei of the ATII cells, as well as the rER tubules in the 
ATII cells, which had a spiral-shaped appearance after treatment with atorvastatin 
1.0 mg/kg/d. These findings suggest that the ATII cells were undergoing apop-
totic processes. Apoptosis is a well-defined programmed cell-death response that
results in characteristic morphologic changes (eg, cell shrinkage, condensation,
and fragmentation of nuclear material).8,20 Some studies have indicated that stat-
ins are associated with apoptosis in different cancer types21–25 and in activated
liver cells.26
Lee et al16 found that simvastatin inhibited lung-cell destruction caused by chronic
cigarette smoking. Specifically, the authors reported that simvastatin (5 mg/kg) 
decreased lung parenchymal destruction, inflammatory infiltration, and pulmonary 
hypertension induced by chronic cigarette smoking and concluded that simvastatin
prevented smoking-induced lung damage via pleiotropic effects. Our findings regard-
ing atorvastatin 0.5 mg/kg/d were consistent with the findings of Lee et al.
Limitations
One limitation was the small sample size. Our study did not include a group that
was not exposed to smoke and did not receive atorvastatin. Quantitative assessment 
could not be performed for the ultrastructural examination and comparison of the
tissues because of the TEM technique. 
Although apoptosis in the 1.0-mg group suggests that the higher dose of atorva-
statin may be associated with cellular damage, this study was not designed or powered
to evaluate atorvastatin apoptosis causality. Comprehensive, well-designed, and ade-
quately powered studies are needed to investigate the dose–response relationship of 
atorvastatin with cellular damage.
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CONCLUSIONS
The administration of atorvastatin 0.5 mg/kg/d was associated with some attenuation of 
lung injury caused by smoke inhalation in these rats. However, atorvastatin 1.0 mg/kg/d 
was associated with lung damage. Future studies are needed to evaluate the dose-
response relationship of atorvastatin to smoking-induced alveolar damage.
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